



# Health Status in the Islamic Republic of Iran, Middle East and North Africa Countries: Implications for Global Health

*Hossein MIRZAEI<sup>1</sup>, Zhaleh ABDI<sup>2</sup>, \*Elham AHMADNEZHAD<sup>2</sup>, Mahshad GOHRIMEHR<sup>2</sup>, Elham ABDALMALEKI<sup>2</sup>, Rezvaneh ALVANDI<sup>2</sup>, Iraj HARIRCHI<sup>3</sup>*

1. Department of Biostatistics and Epidemiology, School of Health, Kerman University of Medical Sciences, Kerman, Iran
2. National Institute for Health Research (NIHR), Tehran University of Medical Sciences, Tehran, Iran
3. School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

\*Corresponding Author: Email: elhamahmadnezhad@gmail.com

(Received Mar 2019; accepted 11 May 2019)

## Abstract

**Background:** The aim of this study was to evaluate the health status of Iranians following the sustainable development goals (SDGs) introduction and to compare with those of the Middle East and North Africa region (MENA) and global.

**Methods:** This comparative study used secondary data analysis to investigate socio-demographic and health status indicator. The sources included census, population-based surveys and death registries. The indicators in MENA were obtained from international databases including WHO, the World Bank and the Institute for Health Assessment and Evaluation (IHME).

**Results:** Life expectancy and human development index increased following the HTP implementation. Among causes of death, 74.6% were attributed to non-communicable diseases (NCDs). There was an increasing trend in risk factors for NCDs in Iran, while at the same time Neonatal, infant and under-5 mortality rates reduced. Compared to the MENA, Iran has a lower maternal mortality ratio, neonatal, infant, and under-5 mortality rates, and a higher life expectancy. NCDs and road injuries accounted for a larger portion of disability-adjusted life years in Iran compared to the MENA and worldwide.

**Conclusion:** Actions against communicable diseases and road traffic injuries are required together with continued efforts to address NCDs. Although Iran does not have a low global SDGs Index ranking, there is a need to develop a roadmap to accelerate achieving global health goals and SDGs implementation.

**Keywords:** Health status; Non-communicable disease; Iran; MENA region; Global health; Sustainable development goals

## Introduction

The burden of infectious diseases has reduced globally through the strengthening of the health systems and development of primary health care (PHC) strategy (1, 2). However, health systems still face a number of challenges, which include demographic and epidemiological transitions and shifting of the burden of non-communicable diseases (3). SDGs, introduced as a main post-2015

agenda, will enable countries to provide health for all (4). Health is centrally placed in the SDGs (5, 6).

The Alma-Ata Declaration was the first international declaration that advocated PHC (7). Improvements in health status with PHC implementation in Iran have changed disease patterns (8). Forty years after the launch of PHC, universal

health coverage (UHC) as the central target of SGDs has been given a prominent place in the post-2015 global agenda. Countries have gradually put the program on their agenda since 2000 (9). Iran made a commitment to make UHC a priority. Iran initiated a health reform, called Health Transformation Plan (HTP), in early 2014 with the prime intention to achieve UHC. The HTP aimed at reducing the shortage and controlling the price of essential medicines.

With a considerable increase in the Ministry of Health and Medical Education (MoHME)'s budget, insurance coverage was extended to approximately 10 million people. A number of other interventions were introduced to reduce Iranian OOP payments to 20% or less of the Total Health Expenditure (THE). A few months later, the next phase of the HTP started scaling up the primary health services coverage. One of the main interventions implemented in Oct 2014 to reduce OOP payments was updating relative value units of health services to better reflect the cost of services in both public and private sectors (6). Health indicators are employed as benchmark to track progress towards achieving broad health system objectives as well as evaluate the performance of health systems and the success of health programs. Health indicators are also employed to examine the differences in health status within and between countries (9).

In this study, health indicators were used as benchmark to determine whether the stated goals of health programs and UHC in Iran have been achieved. Furthermore, health status indicators of Iran were compared with those of countries located in the MENA and the global average.

## Methods

This comparative study used secondary data analysis. The indicators definitions and data collection methods are as follows:

### *Socioeconomic indicators*

1. Demographic indicators:  
The components are: i) Total population, ii) Average population growth rate (GR), iii)

Population over 65 yr of age, iv) Urban population in Iran in 2016 were compared with those in the MENA and the world. Data for MENA obtained from the World Bank database and Data for Iran collected from censuses conducted in 2006, 2011 and 2016.

2. Human Development Index (HDI):  
HDI including long and healthy life, being knowledgeable and have a decent standard of living. The health dimension is assessed by life expectancy at birth; the education dimension is measured by mean of years of schooling for adults aged 25 yr and more and expected years of schooling for children of school entering age. The standard of living dimension is measured by gross national income per capita (GNI) per capita (based on 2011 Purchasing Power Parity- \$) (1, 5, 10). Data on HDI for MENA and Iran were collected from the United Nations database in 2015.

### *Health status and risk factors*

#### 1. Life expectancy (LE):

- **LE at birth:**

The average number of years that a newborn could expect to live if he or she were to pass through life exposed to the sex- and age-specific death rates prevailing at the time of birth, for a specific year, in a given country, territory or geographical area. LE at birth is derived from life tables and is based on sex- and age-specific death rates. United Nations (UNs) values for LE at birth correspond to mid-year estimates, consistent with the corresponding UNs fertility medium-variant quinquennial population projections. The IHME database was used to compare LE in Iran to MENA and global average in 2015 (5,10).

- **Healthy LE (HALE):**

Average number of years that a person can expect to live in "full health" by taking into account years lived in less than full health due to disease and/or injury (5, 10). The source of information is the same source of LE at birth.

**2. Main causes of death and disease burden:**

• **Main causes of deaths:**

Measuring how many people die each year and why they have died is one of the most important means –along with gauging how various diseases and injuries are affecting the living– for assessing the effectiveness of a country’s health system. These indicators for Iran were obtained from Iran’s Health Profile Reports (10). These indicators in the MENA and the world were extracted from IHME global burden of disease database.

• **DALYs)**

Years of healthy life lost to premature death and disability. DALYs are the sum of years of life lost (YLLs) and years lived with disability (YLDs) (1, 10). The source of information is the same source of main cause of deaths.

**3. Neonatal, infant and under-5 mortality rates (per 1000 live births):**

• **Neonatal mortality rate (NMR)**

Number of deaths during the first 28 completed days of life per 1000 live births in a given year or period. Number of children who died during the first 28 d of life divided by number of live births (years of exposure) used for calculation (1). Data from Iran’s Multiple-Indicator Demographic and Health Surveys (IrMIDHS conducted in 2000, 2010), surveillance routine systems and death registries were used to capture these indicators for Iran. The World Bank database was used to check these indicators in the MENA and the world.

• **Infant mortality rate (IMR) and Under-5 mortality rates (U-5 MR):**

The probability that a child born in a specific year or period will die before reaching the age of 1 (for IMR) and 5 (for U-5MR) year, if subject to age-specific mortality rates of that period, expressed as a rate per 1000 live births. Number of children who died before their first birthday (0–11 months of age) divided by number of live births (years of exposure) used for calculation (1). For U-5MR Number of deaths among children aged 0–4

yr (0–59 months of age divided by number of live births (person-years of exposure) used for calculation. Source of information is the same source of NMR.

**4. Maternal Mortality Ratio (MMR):**

MMR (per 100,000 live births): Number of maternal deaths per 100,000 live births during a specified time, usually one year. Number of maternal deaths divided by number of live births used for calculation (5). Information on this indicator was collected from the MoHME reports. The WHO mortality database was the main source for MMR in the MENA and the world.

**5. Risk Factors:**

**Tobacco use:**

Prevalence of current tobacco use among persons aged 18+ yr “smoked tobacco products”. “Current users” include both daily and non-daily users of smoked or smokeless tobacco divided by number of current tobacco users aged 18+ yr used for calculation (3, 5). Data were extracted from NCDs Risk Factor Surveys (STEPS) conducted in 2000, 2010 and 2016. WHO database was used to obtain these indicators for MENA and the global.

**Prevalence of overweight in persons aged 18+ yr:**

Percentage of adults (18+ yr) who are overweight (defined as having a BMI  $\geq 25$  kg/m<sup>2</sup>) and obese (defined as having a BMI  $\geq 30$  kg/m<sup>2</sup>). Number of respondents aged 18+ yr overweight divided by all respondents of the survey aged 18+ yr used for calculation (3, 5). The source of information is the same source of tobacco use.

**Raised blood pressure (BP) and Blood glucose:**

Prevalence of raised BP among persons aged 18+ yr defined as systolic BP  $\geq 140$ mmHg and/or diastolic BP  $\geq 90$ mmHg. Number of respondents with systolic BP  $\geq 140$ mmHg or diastolic BP  $\geq 90$ mmHg divided by all respondents of the survey aged 18+ yr used for calculation A fasting blood sugar level higher than 126mg/dL considered as diabetes (3, 5).

The source of information are the same source of tobacco use.

All estimations were adjusted based on the population size. There was no possibility for age and sex adjustment due to data non-availability.

The following 19 countries of the MENA were included in this study: Algeria, Bahrain, Djibouti, Egypt, Iran, Israel, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Qatar, Saudi Arabia, Syria, Tunisia, the United Arab Emirates and Yemen. Palestine was excluded from the study due to lack of data.

**Ethical approval**

Ethics approval for this study was obtained from Human Research Ethics Committee of the I.R. of Iran’s National Institute of Health Research (Ethics ID: IR.TUMS.NIHR.REC.1396.36).

**Results**

**Socioeconomic characteristic**

**Demographic indicators:** Iran, accounts for 18.3% of MENA and 1% of the world's population. The annual population GR in Iran is 1.24%, which is lower than the annual population GR in the MENA (1.73), but is higher than the annual population GR in the world (1.15). The proportion of the population aged 65 yr and above in Iran is 6.1%, which is higher than the MENA and lower than the global average. In 2016, the percentage of the total population living in urban areas of Iran was 74%, which is higher than the average urbanization rate in the MENA and the world (Table 1).

**Table 1:** Socioeconomic and health indicator in Iran, MENA and the world

<i>Variable</i>	<i>IRAN and Rank (In MENA)</i>	<i>MENA</i>	<i>Global</i>
Population (2016) – (x1000)	79,926 (2)	436,720	7,442,135
65yr and above (% of total)	6.1 (6)	4.85	8.48
Urban Population (% of Total) (2016)	74 (14)	64.5	54.29
HDI (2015)	0.774 (8)	0.709	0.717
Mean years of schooling	8.8 (8)	7.3	8.3
GNI per capita	16,395 (8)		14,447

**Human development:** The HDI in Iran is 0.774 (2015), which is higher than the global average and MENA’s average. Iran ranks 8 in the MENA and 69 in the world in terms of HDI. The average years of schooling in Iran is 8.8 yr.

GNI per capita based on purchasing power parity (PPP- constant price of the international dollar in

2011) is \$ 16,395 in Iran, which is higher than the world's GNI per capita and is lower than the average in the MENA. According to the table, Iran has an increasing population GR with increasing average population age (Table 2).

**Table 2:** Trends in Demographic and Socioeconomic indicators in Iran

<i>Indicator</i>	<i>2000</i>	<i>2010</i>	<i>2015</i>
Population– (x1000)	70,495	75,149	79,926
65y and above (% of total)	5.2	5.7	6.1
Mean Age of population	24.7	29.8	31.1
Urban Population (% of Total)	68.9	71.4	74
HDI -2015	0.666	0.755	0.774
Mean years of schooling	6.2	8.2	8.8
GNI per capita	11348	17520	16395

### Child and maternal mortality

In 2015, U-5MR in Iran was 15.5 per 1,000 live births. The IMR was 13 per 1,000 live births. The

NMR was 9.6 per 1,000 live births. The U-5MR and NMR decreased in 2015 compared to 2010 and 2005 in Iran (Fig. 1).




Fig. 1: Trends in neonatal, infant and under 5 mortality rates in Iran

In 2016, the MMR in Iran was 19, which is lower than the MMR in the MENA [81] and the world [216]. In 2016, the MMR (27) decreased by 7.4%

compared to 2010. In 2000, MMR [51] decreased by 47% (Table 3).

Table 3: LE, child mortality rates and MMR Iran, MENA and the world

Variable	IRAN and Rank (In MENA)	MENA	Global
LE -2015	75.5 (8)	73.2	72.5
HALE at Birth -2015	64.79 (10)	62.5	63.12
NMR -2016	9.6 (12)	14.6	18.6
IMR -2016	13 (12)	20.1	30.5
U-5MR -2016	15.5 (12)	24	40.8
MMR -2016	19 (10)	81	216

### Mortality and burden of disease

LE at birth in Iran is 75.6 yr. LE among Iranians increased by 2.5% from 2000 to 2010 and 2.6% from 2010 to 2015. In 2016, 79.7% of all deaths and 74.1% of DALYs were due to NCDs. In the

MENA, these figures were 72.2% and 63.9%, respectively. Globally, 72.2% of all deaths and 61.3% of DALY were attributed to NCDs (Fig. 2).

Global	MENA	Iran
Cardiovascular Disease	Cardiovascular diseases	Cardiovascular diseases
Neoplasm	Neoplasms	Neoplasms
Diarrhea/LRI/other	Diabetes/urog/blood/endo	Diabetes/urog/blood/endo
Chronic respiratory	Diarrhea/LRI/other	Transport injuries
Diabetes/urog/blood/endo	Transport injuries	Neurological disorders
Neurological disorders	Neurological disorders	Neonatal disorders
HIV/AIDS & Tuberculosis	War & Disaster	Chronic respiratory
Unintentional injuries	Neonatal disorders	Diarrhea/LRI/other
Neonatal Disorder	Chronic respiratory diseases	Unintentional injuries
Transport injuries	Cirrhosis	Other non-communicable disease

Main Cause of Death in Iran, MENA Region and the world in 2016

Global	MENA	Iran
Cardiovascular Disease	Cardiovascular diseases	Cardiovascular diseases
Diarrhea/LRI/other	Other non-communicable disease	Mental & Substance use
Neoplasms	Mental & Substance use	Other non-communicable disease
Other non-communicable disease	Neonatal disorders	Musculoskeletal disorders
Neonatal Disorder	Diabetes/urog/blood/endo	Diabetes/urog/blood/endo
Mental & Substance use	Diarrhea/LRI/other	Neoplasms
Musculoskeletal disorders	Musculoskeletal disorders	Transport injuries
Diabetes/urog/blood/endo	Neoplasms	Neonatal Disorder
Unintentional injuries	War & Disaster	Neurological disorders
Neonatal disorders	Transport injuries	Unintentional injuries

Main Cause of DALY in Iran, MENA Region and the world in 2016




Fig. 2: Main Cause of DALY in Iran, MENA and the world in 2016

Infectious diseases, maternal, child mortality, and nutritional factors account for 7.7%, 13.2% and 19.3% of deaths in Iran, MENA and the world, respectively (Fig. 2).

**Risk factors**

Figure 3 shows the prevalence of NCDs risk factors. Figure 4 compares the prevalence of smoking, overweight and obesity and raised BP in 2005, 2010 and 2016 in Iran. The prevalence of

increased in 2016 compared to 2005. The prevalence of obesity and overweight (BMI > 25) among Iranians over the age of 18 yr was 59.3%. The prevalence of overweight and obesity increased in 2016 compared to 2005. The prevalence of hypertension among men and women was 25.7% and 28.2%, respectively. The prevalence of high blood sugar in males and females was 11.4% and 12.9%, respectively.




Fig. 3: Prevalence of NCDs risk factors in Iran, MENA and the world




Fig. 4: FTrend of risk factors for NCDs in Iran

## Discussion

The aim of the study was to compare the health status indicators in Iran with those of MENA

and global. Compared to the MENA, Iran has a lower maternal mortality ratio, neonatal, infant, and U-5MR, and a higher LE and HDI. LE and HDI increased following the HTP implementa-

tion. Among causes of death, 74.6% were attributed to non-communicable diseases. There was an increasing trend in risk factors for non-communicable diseases (NCDs) in Iran, while at the same time NMR, IMR and U-5MR reduced. NCDs and road injuries accounted for a larger portion of DALYs (Disability Adjusted Life Years) in Iran compared to the MENA and worldwide.

Measurements of health status allow the identification of health priority issues as well as monitor the progress made towards achieving the SDGs and UHC (5, 6). Determination of health status indicators can help to set benchmark for attaining UHC. It can also assist with monitoring of health status trends and providing benchmarks for assessing the success of programs in achieving the desired targets (9, 10). This study was aimed at comparing Iran's health indicators with the health indicators of countries located in MENA and the global average.

The indicators' trends suggested that LE increased following the implementation of the HTP. There was also an improvement in mortality indicators during this period. However, there was an increase in the contribution of NCDs and their underlying risk factors to the burden of disease during this period. Given the relatively short period between the HTP implementation and evaluation, these changes may not be attributable to the introduction of the HTP. Nevertheless, this study can be used as a benchmark to evaluate the long-term effects of future reforms.

Health status indicators of Iran were compared with the average of the MENA. This helps to compare countries' health status indicators with the region's average at a glance. In addition to the region's average, we compared Iran's health status indicators with those of MENA countries. We did this for two reasons. The first reason is related to the mean property, heavily influenced by outliers. If the situation of one or more countries is much different from other countries, it can influence the average. Secondly, countries located in the MENA are significantly different in terms of socioeconomic status and health status. For instance, there is a wide variation across

countries' HDI such that there are countries with very high HDI or very low HDI in the region. Therefore, Iran's indicators should be compared with each country's indicators.

Maternal, infant, neonatal and u-5 mortality rates in Iran are lower than the MENA and global. LE at birth was higher than the MENA and global average. The trend of maternal and child mortality in Iran is on the decrease; this is consistent with previous studies (11, 12). This significant improvement in the health status indicators can be attributed to the successful implementation of the PHC program in Iran (13). In terms of the HDI, Iran occupies the eighth position in the region. Qatar had the highest in this region in 2015 (0.85). Saudi Arabia and the United Arab Emirates (UAE) were ranked second and third. After Iran, Jordan, Iraq and Yemen ranked 9th to 11th, respectively (14). The HDI in Iran is higher than the global average and that of the MENA.

Qatar, Saudi Arabia, UAE, Bahrain, Kuwait and Oman have HDI higher than 0.8 and are among the countries with very high HDI. Iran, Algeria, Lebanon, Jordan, Tunisia and Libya have a HDI between 7 and 7.99 and are considered to have a high HDI. Egypt, Iraq and Morocco, which have HDI between 0.55 and 0.69, are among the countries with medium HDI. In Syria, Sudan, Yemen and Djibouti, HDI is below 0.55. These countries are considered to have low HDI. There was a change in HDI ranking in the MENA in 2016. Saudi Arabia witnessed the highest increase in HDI value during 2010-2015 and ranked 38th in the 2015 world rankings. Moroccan HDI ranking improved four places, Iran HDI ranking improved three places, and Qatar HDI ranking improved two places during the period. In contrast, the HDI ranking of countries such as Libya, Syria, Yemen and Lebanon dropped by 35, 29, 12 and 12 points, respectively (14).

The impact of war on health and consequently on HDI must be taken into account while considering countries HDI (15, 16). Review of changes in HDI index shows that although the ranking of most countries in the MENA changed minimally, HDI in countries like Libya, Syria, Lebanon and Yemen changed tremendously (12



to 35 ranks). A review of the causes of death in these countries showed that although in the majority of MENA countries, cardiovascular diseases are the main causes of mortality and morbidity, civil war and conflict in Syria was the first cause of death (45% deaths); in Iraq and Yemen, it is the second leading cause of death and in Libya, it is the fourth cause of death (10). Iran's HDI has increased favorably and, it is anticipated that by 2030 (targeted year to achieve SDGs) Iran will be among the countries with a high HDI.

NCDs and road accidents in Iran account for more deaths and Years of Life Lost (YLL) due disability compared to the MENA and the world. This could be due to the low mortality induced by infectious diseases, maternal mortality, child mortality and nutritional factors. The results of the current study and those of other studies (17) showed that the burden of NCDs continue to rise rapidly in Iran and the MENA. The number of premature deaths due to NCDs will increase significantly in the future. Furthermore, there is a difference in the ranking of the causes of death in Iran, the MENA and the world at large. Deaths from disasters and war are not among the 10 leading causes of death and disability in Iran and the world at large. However, in the MENA, it is the 7th leading cause of death and disability. This is due to civil wars and conflicts in four MENA countries: Syria, Iraq, Yemen and Libya. Syria's civil war accounted for 45% of deaths and 47.2% of DALY in 2016. It accounts for 11.1% of deaths and 12.3% of DALY in Iraq, 14.4% of deaths and 13.3% of DALY in Yemen. However, in Iran, war and disasters accounts for 0.18% of deaths and is the 20th leading cause of death. It accounts for 0.65% of the DALYs and twenty-first leading cause of DALYs (10).

Given the growing burden of NCDs, in 2013, WHO initiated a global action plan to forestall and control NCDs. The most important objective is a 25% reduction in the deaths from NCDs (13). Following the introduction of HTP, national action plan was developed to monitor and assess all measures aimed at controlling NCDs and risk factors in Iran (18). The plan was aimed at re-jigging health systems to include NCDs and mental

health services in primary health services. Although many proven interventions for NCDs were considered in the plan, more targeted interventions are needed to reduce the risk factors of NCDs among all subgroups of population. The effects of these interventions should continuously be monitored and evaluated.

This study had some limitations that future studies can take into account. We studied only the health status indicators and did not include health systems financing indicators. For future studies, we recommend to include Iran's health system financing indicators and compare them with those of MENA countries. The impact assessment of the HTP was not carried out in the current study due to the aim of paper. Hence, the HTP effects on health indicators and its weak or strength compared to other health programs conducted in the other countries will be investigated more in future.

## Conclusion

Indicators of child and maternal mortality in Iran are lower than in MENA and global. Indicators related to HDI in Iran was better than MENA and global. Main cause of death is approximately same in Iran, MENA and global but there are some difference like as war and disaster that there are seventh cause of death in MENA but it is not between top 10 cause of death in Iran and global. Death from HIV/AIDS in Iran and MENA is not between first 10 causes, but global is seventh cause. The prevalence of smoking in Iran lower than the global and the MENA, The prevalence of obesity and overweight (BMI > 25) among Iranians was lower than the prevalence of obesity and overweight in the MENA and higher than the prevalence of overweight and obesity in the world. The prevalence of hypertension among Iranian is higher than in the MENA and the world. International organizations should play a constructive role in the support of peace in the region and enhance their role in the fight against terrorism, which can be very effective in improving health and reducing mortality among the involved countries.

## Ethical considerations

Ethical issues (Including plagiarism, informed consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc.) have been completely observed by the authors.

## Acknowledgements

This study was the result of a research project approved by the Research Council of the National Institute of Health Research (code: 241/M/9696).

## Conflict of interest

Non-declared.

## References

1. Claeson M, Waldman RJ (2000). The evolution of child health programmes in developing countries: from targeting diseases to targeting people. *Bull World Health Organ*, 78:1234-45.
2. Dye C(2014). After 2015: infectious diseases in a new era of health and development. *Philos Trans R Soc Lond B Biol Sci*, 369(1645):20130426.
3. Arredondo A, Aviles R(2015). Costs and Epidemiological Changes of Chronic Diseases: Implications and Challenges for Health Systems. *PLoS ONE*, 10(3):e0118611.
4. Pablos-Mendez A, Cavanaugh K, Ly C(2016). The new era of health goals: universal health coverage as a pathway to the Sustainable Development Goals. *Health Syst Reform*, 2(1):15-17.
5. Asbu EZ, Masri MD, Kaissi A(2017). Health status and health systems financing in the MENA region: roadmap to universal health coverage. *Glob Health Res Policy*, 2(1):25.
6. Mousavi SM, Sadeghifar J(2016). Universal health coverage in Iran. *Lancet Glob Health*, 4(5):e305-e6.
7. DeLusignan S, Teasdale S, Little D, et al (2004). Comprehensive computerised primary care records are an essential component of any national health information strategy: report from an international consensus conference. *J Innov Health Inform*, 12(4):255-64.
8. Naghavi M, Shahraz S, Sepanlou SG, et al (2014). Health transition in Iran toward chronic diseases based on results of Global Burden of Disease 2010. *Arch Iran Med*, 17(5):321-35.
9. Mboi N, Murty Surbakti I, Trihandini I, et al(2018). On the road to universal health care in Indonesia, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet (London, England)*, 392(10147):581-91.
10. World Health Organization (2011). Monitoring, evaluation and review of national health strategies: a country-led platform for information and accountability. [http://www.who.int/healthinfo/country\\_monitoring\\_evaluation/1085\\_IER\\_131011\\_web.pdf](http://www.who.int/healthinfo/country_monitoring_evaluation/1085_IER_131011_web.pdf)
11. Lozano R, Wang H, Foreman KJ, et al(2011). Progress towards Millennium Development Goals 4 and 5 on maternal and child mortality: an updated systematic analysis. *Lancet*, 378(9797):1139-65.
12. Moazzeni MS(2013). Maternal mortality in the Islamic Republic of Iran: on track and in transition. *Matern Child Health J*, 17(4):577-80.
13. Asadi-Lari M, Sayyari A, Akbari M, Gray D(2004). Public health improvement in Iran—lessons from the last 20 years. *Public Health*, 118(6):395-402.
14. Jahan S(2017). Human Development Report 2016—Human Development for Everyone. [http://hdr.undp.org/sites/default/files/2016\\_human\\_development\\_report.pdf](http://hdr.undp.org/sites/default/files/2016_human_development_report.pdf)
15. Sharara SL, Kanj SS(2014). War and infectious diseases: challenges of the Syrian civil war. *PLoS Pathog*, 10(11):e1004438.
16. Dewachi O, Skelton M, Nguyen V-K, et al (2014). Changing therapeutic geographies of the Iraqi and Syrian wars. *Lancet*, 383(9915):449-57.
17. Forouzanfar MH, Sepanlou SG, Shahraz S, et al(2014). Evaluating causes of death and morbidity in Iran, global burden of diseases, injuries, and risk factors study 2010. *Arch Iran Med*, 17(5):304-20.
18. Peykari N, Hashemi H, Dinarvand R, et al (2017). National action plan for non-communicable diseases prevention and control in Iran; a response to emerging epidemic. *J Diabetes Metab Disord*, 16(1):3.